187.78 USD
+4.64 (+2.53%)
187.79 USD
+0.01 (+0.01%)
We assign a fundamental rating of 5 out of 10 to ICLR. ICLR was compared to 58 industry peers in the Life Sciences Tools & Services industry. ICLR has only an average score on both its financial health and profitability. ICLR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ICLR had positive earnings in the past year.
ICLR had a positive operating cash flow in the past year.
ICLR had positive earnings in each of the past 5 years.
Each year in the past 5 years ICLR had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.63%, ICLR is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
ICLR has a Return On Equity of 6.42%. This is in the better half of the industry: ICLR outperforms 75.86% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.74%, ICLR is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ICLR is significantly below the industry average of 13.53%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.74%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROIC | 6.74% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
ICLR has a Profit Margin of 7.40%. This is in the better half of the industry: ICLR outperforms 75.86% of its industry peers.
In the last couple of years the Profit Margin of ICLR has declined.
ICLR's Operating Margin of 13.99% is fine compared to the rest of the industry. ICLR outperforms 75.86% of its industry peers.
ICLR's Operating Margin has been stable in the last couple of years.
The Gross Margin of ICLR (28.15%) is worse than 74.14% of its industry peers.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
ICLR has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ICLR has less shares outstanding than it did 1 year ago.
ICLR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ICLR has been reduced compared to a year ago.
2.2 Solvency
ICLR has an Altman-Z score of 2.13. This is not the best score and indicates that ICLR is in the grey zone with still only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score (2.13) which is in line with its industry peers.
ICLR has a debt to FCF ratio of 3.53. This is a good value and a sign of high solvency as ICLR would need 3.53 years to pay back of all of its debts.
ICLR's Debt to FCF ratio of 3.53 is fine compared to the rest of the industry. ICLR outperforms 79.31% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ICLR is not too dependend on debt financing.
ICLR has a Debt to Equity ratio of 0.31. This is comparable to the rest of the industry: ICLR outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Altman-Z | 2.13 |
ROIC/WACC0.8
WACC8.47%
2.3 Liquidity
A Current Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.06, ICLR is doing worse than 87.93% of the companies in the same industry.
A Quick Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR's Quick ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.99%.
The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
The Revenue has decreased by -2.46% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
3.2 Future
The Earnings Per Share is expected to grow by 5.61% on average over the next years.
The Revenue is expected to grow by 2.38% on average over the next years.
EPS Next Y-4.67%
EPS Next 2Y-0.67%
EPS Next 3Y3%
EPS Next 5Y5.61%
Revenue Next Year-2.45%
Revenue Next 2Y-0.8%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 14.24 indicates a correct valuation of ICLR.
ICLR's Price/Earnings ratio is rather cheap when compared to the industry. ICLR is cheaper than 96.55% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.37. ICLR is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.60, the valuation of ICLR can be described as correct.
96.55% of the companies in the same industry are more expensive than ICLR, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.20. ICLR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.24 | ||
| Fwd PE | 13.6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ICLR is valued cheaply inside the industry as 98.28% of the companies are valued more expensively.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 93.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.87 | ||
| EV/EBITDA | 11.35 |
4.3 Compensation for Growth
The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.93
EPS Next 2Y-0.67%
EPS Next 3Y3%
5. Dividend
5.1 Amount
ICLR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
187.78
+4.64 (+2.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.62%
Inst Owner Change-0.44%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap14.34B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts76.67
Price Target209.8 (11.73%)
Short Float %2.51%
Short Ratio1.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-1.3%
PT rev (3m)-5.91%
EPS NQ rev (1m)-0.55%
EPS NQ rev (3m)-5.68%
EPS NY rev (1m)-1.01%
EPS NY rev (3m)-1.62%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)0.24%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.24 | ||
| Fwd PE | 13.6 | ||
| P/S | 1.77 | ||
| P/FCF | 14.87 | ||
| P/OCF | 12.57 | ||
| P/B | 1.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.35 |
EPS(TTM)13.19
EY7.02%
EPS(NY)13.81
Fwd EY7.36%
FCF(TTM)12.63
FCFY6.72%
OCF(TTM)14.93
OCFY7.95%
SpS106.11
BVpS122.25
TBVpS-38.98
PEG (NY)N/A
PEG (5Y)0.93
Graham Number190.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 6.98% | ||
| ROICexgc | 176.34% | ||
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% | ||
| FCFM | 11.9% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 45.31% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.92% | ||
| Profit Quality | 160.84% | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 2.13 |
F-Score6
WACC8.47%
ROIC/WACC0.8
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.67%
EPS Next 2Y-0.67%
EPS Next 3Y3%
EPS Next 5Y5.61%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.45%
Revenue Next 2Y-0.8%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year0.82%
EBIT Next 3Y3.29%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%
ICON PLC / ICLR FAQ
Can you provide the ChartMill fundamental rating for ICON PLC?
ChartMill assigns a fundamental rating of 5 / 10 to ICLR.
What is the valuation status of ICON PLC (ICLR) stock?
ChartMill assigns a valuation rating of 6 / 10 to ICON PLC (ICLR). This can be considered as Fairly Valued.
Can you provide the profitability details for ICON PLC?
ICON PLC (ICLR) has a profitability rating of 6 / 10.
How financially healthy is ICON PLC?
The financial health rating of ICON PLC (ICLR) is 5 / 10.
What is the earnings growth outlook for ICON PLC?
The Earnings per Share (EPS) of ICON PLC (ICLR) is expected to decline by -4.67% in the next year.